Local and systemic immunologic effects of perfusion therapy for malignant melanoma.
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000494:pharmacology; D010478:Chemotherapy, Cancer, Regional Perfusion; D003609:Dactinomycin / Q000627:therapeutic use; D005121:Extremities; D006084:Graft Rejection / Q000187:drug effects; D006801:Humans; D007165:Immunosuppression Therapy; D037102:Lectins; D008213:Lymphocyte Activation / Q000187:drug effects*; D008212:Lymphocyte Depletion; D008214:Lymphocytes / Q000276:immunology; D008466:Mechlorethamine / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology; D008558:Melphalan / Q000627:therapeutic use; D011379:Prognosis; D013301:Streptolysins; D013312:Stress, Physiological
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D037102:Lectins; D013301:Streptolysins; D003609:Dactinomycin; D008466:Mechlorethamine; D008558:Melphalan